Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
4
×
life sciences
national blog main
boston
national top stories
san francisco blog main
san francisco top stories
biotech
deals
new york blog main
new york top stories
startups
vc
accent therapeutics
aducanumab
ally bridge group
alzheimer's disease
amblyotech
asklepios biopharmaceutical
big data analytics
bioeurope
biogen
biomarin pharmaceutical
biontech
blackrock
boehringer ingelheim
boulder/denver blog main
boulder/denver top stories
brainvectis
c. greg guyer
cancer
cara therapeutics
casdin capital
clinical trials
crispr
curevac
david walt
deerfield management
detroit blog main
What
bio
4
×
medicines
4
×
new
diseases
ipo
activity
analysis
approvals
bets
biogen
biotech
bring
cancer
clamped
comes
companies
company
covid
create
crispr
cut
date
deal
delays
develop
developing
diagnostic
drug
economic
editing
effective
employing
enticed
evidence
fast
fda
fix
gene
genetic
goldfinch
Language
unset
Current search:
medicines
×
" boston top stories "
×
bio
×
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
5 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines